Claims
- 1. A method of treating a human subject with cancer, comprising administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution,
wherein
the virus binds specifically to the leukocytes; and the ratio of plaque-forming units of the virus to number of leukocytes in the composition is at least 1:100, thereby treating the subject.
- 2. The method of claim 1, wherein the leukocytes are leukocytes of the subject.
- 3. The method of claim 1, wherein the leukocytes are leukocytes of a donor other than the subject.
- 4. The method of claim 1, wherein the leukocytes are active.
- 5. The method of claim 1, wherein the leukocytes are inactive.
- 6. The method of claim 1, wherein the leukocytes are cultured.
- 7. The method of claim 6, wherein the cultured leukocytes comprise an immortalized cell line.
- 8. The method of claim 7, wherein the immortalized cell line is U-937 or KG-1.
- 9. The method of claim 1, wherein the leukocytes are leukocytes isolated by leukopheresis.
- 10. The method of claim 1, wherein the pharmaceutical composition comprises the oncolytic virus suspended in whole blood.
- 11. The method of claim 1, wherein the leukocytes are monocytes.
- 12. The method of claim 1, wherein the leukocytes are neutrophils.
- 13. The method of claim 1, wherein the leukocytes are lymphocytes.
- 14. The method of claim 13, wherein the lymphocytes are tumor-infiltrating lymphocytes.
- 15. The method of claim 1, wherein the virus is of low to moderate virulence.
- 16. The method of claim 1, wherein the virus is a clonal virus.
- 17. The method of claim 1, wherein the ratio of plaque-forming units of the virus to number of leukocytes in the composition is at least 1:1.
- 18. The method of claim 1, wherein the virus is selected from the group consisting of a Newcastle Disease Virus, a Mumps Virus, a Measles Virus, a Vesicular Stomatitis Virus, a Para-influenza Virus, an Influenza Virus, an Adenovirus, a Herpes I Virus, a Vaccinia Virus, and a Reovirus.
- 19. The method of claim 18, wherein the virus is a Newcastle Disease Virus.
- 20. The method of claim 19, wherein the virus is a Newcastle Disease Virus of moderate virulence.
- 21. The method of claim 18, wherein the ratio of plaque-forming units of the virus to number of leukocytes in the composition is from about 1:1 to about 200:1.
- 22. The method of claim 21, wherein the ratio is about 200:1.
- 23. The method of claim 1, wherein the effective amount is a daily dosage containing from 6×106 to 6×1010 leukocytes per square meter of patient surface area.
- 24. The method of claim 23, wherein the daily dosage contains about 6×107 leukocytes per square meter of patient surface area.
- 25. The method of claim 23, wherein the daily dosage is administered in single administration.
- 26. The method of claim 23, wherein the daily dosage is administered at a frequency of from one to seven times in a one-week period.
- 27. The method of claim 1, wherein the composition is administered intravenously.
- 28. The method of claim 27, wherein the volume of the composition administered is from twenty-five milliliters to one liter.
- 29. The method of claim 1, wherein the composition is administered intratumorally.
- 30. The method of claim 29, wherein the volume of composition administered is from one hundred microliters to ten milliliters per tumor mass.
- 31. The method of claim 1, wherein the composition is administered intraperitoneally.
- 32. The method of claim 31, wherein the volume of composition administered is up to two liters.
- 33. The method of claim 1, wherein the composition is administered intravesicularly.
- 34. The method of claim 33, wherein the volume of composition administered is up to seventy-five milliliters.
- 35. The method of claim 34, wherein the volume of composition administered is from fifty to sixty milliliters.
- 36. The method of claim 1, wherein the cancer is a solid tumor and the composition is administered intravenously or intratumorally.
- 37. The method of claim 1, wherein the cancer is other than a solid tumor and the composition is administered intravenously.
- 38. The method of claim 37, wherein the cancer is leukemia.
- 39. A method of treating a human subject with cancer, comprising administering to the subject an amount of a pharmaceutical composition effective to treat the subject, the pharmaceutical composition comprising human cells infected with an oncolytic virus in suspension in a physiologically acceptable solution, wherein the cells are leukocytes or platelets, thereby treating the subject.
- 40. The method of claim 39, wherein the cells are cells of the subject.
- 41. The method of claim 39, wherein the cells are cells of a donor other than the subject.
- 42. The method of claim 39, wherein the cells are cultured.
- 43. The method of claim 42, wherein the cultured cells comprise an immortalized cell line.
- 44. The method of claim 43, wherein the immortalized cell line is U-937 or KG-1.
- 45. The method of claim 39, wherein the cells are leukocytes.
- 46. The method of claim 43, wherein the leukocytes are active.
- 47. The method of claim 43, wherein the leukocytes are inactive.
- 48. The method of claim 39, wherein the leukocytes are monocytes.
- 49. The method of claim 39, wherein the leukocytes are neutrophils.
- 50. The method of claim 39, wherein the leukocytes are lymphocytes.
- 51. The method of claim 50, wherein the lymphocytes are tumor-infiltrating lymphocytes.
- 52. The method of claim 39, wherein the leukocytes are leukocytes isolated by leukopheresis.
- 53. The method of claim 39, wherein the cells are platelets.
- 54. The method of claim 39, wherein the pharmaceutical composition comprises whole blood containing leukocytes or platelets infected with the virus.
- 55. The method of claim 39, wherein the virus is of low to moderate virulence.
- 56. The method of claim 39, wherein the virus is a clonal virus.
- 57. The method of claim 39, wherein the infected cells are at least one-tenth of one percent of the total number of leukocytes and platelets in the composition.
- 58. The method of claim 57, wherein the infected cells are at least thirty percent of the total number of leukocytes and platelets in the composition.
- 59. The method of claim 39, wherein the virus is selected from the group consisting of a Newcastle Disease Virus, a Mumps Virus, a Measles Virus, a Vesicular Stomatitis Virus, a Para-influenza Virus, an Influenza Virus, an Adenovirus, a Herpes I Virus, a Vaccinia Virus, and a Reovirus.
- 60. The method of claim 59, wherein the virus is a Newcastle Disease Virus.
- 61. The method of claim 60, wherein the virus is a Newcastle Disease Virus of moderate virulence.
- 62. The method of claim 39, wherein the effective amount is a daily dosage containing from 6×106 to 6×1010 leukocytes per square meter of patient surface area.
- 63. The method of claim 62, wherein the daily dosage contains about 6×107 leukocytes per square meter of patient surface area.
- 64. The method of claim 62, wherein the daily dosage is administered in a single administration.
- 65. The method of claim 62, wherein the daily dosage is administered at a frequency of from one to seven times in a one-week period.
- 66. The method of claim 39, wherein the effective amount is a daily dosage containing from 109 to 1011 platelets per square meter of patient surface area.
- 67. The method of claim 66, wherein the daily dosage contains about 1011 platelets per square meter of patient surface area.
- 68. The method of claim 66, wherein the daily dosage is administered in a single administration.
- 69. The method of claim 66, wherein the daily dosage is administered at a frequency of from one to seven times in a one-week period.
- 70. The method of claim 39, wherein the composition is administered intravenously.
- 71. The method of claim 70, wherein the volume of the composition administered is from twenty-five milliliters to one liter.
- 72. The method of claim 39, wherein the composition is administered intratumorally.
- 73. The method of claim 72, wherein the volume of composition administered is from one hundred microliters to ten milliliters per tumor mass.
- 74. The method of claim 39, wherein the cancer is a solid tumor and the composition is administered intravenously or intratumorally.
- 75. The method of claim 39, wherein the cancer is other than a solid tumor and the composition is administered intravenously.
- 76. The method of claim 75, wherein the cancer is leukemia.
- 77. The method of claim 39, wherein the composition is administered intraperitoneally.
- 78. The method of claim 77, wherein the volume of composition administered is up to two liters.
- 79. The method of claim 78, wherein the composition is administered intravesicularly.
- 80. The method of claim 79, wherein the volume of composition administered is up to seventy-five milliliters.
- 81. The method of claim 80, wherein the volume of composition administered is from fifty to sixty milliliters.
- 82. The method of claim 39, wherein the virus is replication competent.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application No. 60/290,051, filed May 11, 2001, the content of which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60290051 |
May 2001 |
US |